712 related articles for article (PubMed ID: 30016965)
1. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.
Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M
J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965
[TBL] [Abstract][Full Text] [Related]
2. Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer.
Hu M; Peng S; He Y; Qin M; Cong X; Xing Y; Liu M; Yi Z
Oncotarget; 2015 Jun; 6(17):15348-61. PubMed ID: 25915156
[TBL] [Abstract][Full Text] [Related]
3. Lycorine inhibits the growth and metastasis of breast cancer through the blockage of STAT3 signaling pathway.
Wang J; Xu J; Xing G
Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):771-779. PubMed ID: 28910973
[TBL] [Abstract][Full Text] [Related]
4. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism of lycorine in the treatment of glioblastoma based on network pharmacology and molecular docking.
Su J; Huo M; Xu F; Ding L
Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1551-1559. PubMed ID: 37668687
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
7. Lycorine inhibits breast cancer growth and metastasis via inducing apoptosis and blocking Src/FAK-involved pathway.
Ying X; Huang A; Xing Y; Lan L; Yi Z; He P
Sci China Life Sci; 2017 Apr; 60(4):417-428. PubMed ID: 28251459
[TBL] [Abstract][Full Text] [Related]
8. Identification of molecular anti-metastasis mechanisms of lycorine in colorectal cancer by RNA-seq analysis.
Gao L; Feng Y; Ge C; Xu X; Wang S; Li X; Zhang K; Wang C; Dai F; Xie S
Phytomedicine; 2021 May; 85():153530. PubMed ID: 33761445
[TBL] [Abstract][Full Text] [Related]
9. Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells.
Lefranc F; Sauvage S; Van Goietsenoven G; Mégalizzi V; Lamoral-Theys D; Debeir O; Spiegl-Kreinecker S; Berger W; Mathieu V; Decaestecker C; Kiss R
Mol Cancer Ther; 2009 Jul; 8(7):1739-50. PubMed ID: 19531573
[TBL] [Abstract][Full Text] [Related]
10. Dual blockade of EGFR and PI3K signaling pathways offers a therapeutic strategy for glioblastoma.
Guo T; Wu C; Zhang J; Yu J; Li G; Jiang H; Zhang X; Yu R; Liu X
Cell Commun Signal; 2023 Dec; 21(1):363. PubMed ID: 38115126
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
[TBL] [Abstract][Full Text] [Related]
12. Lycorine inhibits melanoma cell migration and metastasis mainly through reducing intracellular levels of β-catenin and matrix metallopeptidase 9.
Zhang P; Zhang M; Yu D; Liu W; Hu L; Zhang B; Zhou Q; Cao Z
J Cell Physiol; 2019 Jul; 234(7):10566-10575. PubMed ID: 30565685
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib and erlotinib inhibits growth of c-Met
Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
[TBL] [Abstract][Full Text] [Related]
14. Lycorine improves peripheral nerve function by promoting Schwann cell autophagy via AMPK pathway activation and MMP9 downregulation in diabetic peripheral neuropathy.
Yuan Q; Zhang X; Wei W; Zhao J; Wu Y; Zhao S; Zhu L; Wang P; Hao J
Pharmacol Res; 2022 Jan; 175():105985. PubMed ID: 34863821
[TBL] [Abstract][Full Text] [Related]
15. Lycorine inhibits lipopolysaccharide-induced iNOS and COX-2 up-regulation in RAW264.7 cells through suppressing P38 and STATs activation and increases the survival rate of mice after LPS challenge.
Kang J; Zhang Y; Cao X; Fan J; Li G; Wang Q; Diao Y; Zhao Z; Luo L; Yin Z
Int Immunopharmacol; 2012 Jan; 12(1):249-56. PubMed ID: 22155741
[TBL] [Abstract][Full Text] [Related]
16. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
17. Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight.
Lamoral-Theys D; Andolfi A; Van Goietsenoven G; Cimmino A; Le Calvé B; Wauthoz N; Mégalizzi V; Gras T; Bruyère C; Dubois J; Mathieu V; Kornienko A; Kiss R; Evidente A
J Med Chem; 2009 Oct; 52(20):6244-56. PubMed ID: 19788245
[TBL] [Abstract][Full Text] [Related]
18. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
[TBL] [Abstract][Full Text] [Related]
19. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
